HiFiBiO Therapeutics, a US biotherapeutics company, has completed a USD67m Series C financing round, it was reported yesterday.

The funding was headed by new investor, IDG Capital. The present shareholders Sequoia Capital China, VI Ventures, Legend Star Capital, and LYFE Capital continued to invest. New investors Delian Capital, Hanne Capital, and Kite, a Gilead Company, also supported this round.

The company will use the funds from the financing to expand its platform efforts and to accelerate the development of its novel antibody drug pipeline to treat cancer and autoimmune disorders.